When i.p. administered (10 and 20 mg/kg) in a Tg2576 mouse model of AD, it significantly improved cognitive deficit, reduced Aβ accumulation and oxidative damage, and upregulated NRF2 and HO-1 levels, promoting neurogenesis in the mouse hippocampus (147). Here, NFE2L2 is linked to Alzheimer disease.